NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
23 October 2024
| Name: | COGSTATE LTD (CGS) |
| ISIN: | AU000000CGS8 |
| Date of Listing: | 13 February 2004 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 090 975 723ABN: 80 090 975 723
Registration Date: 17 December 1999
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Cogstate Ltd will be lifted immediately following the release by CGS of an announcement regarding a response to an ASX Price Query. | 24/02/2023 |
The company issues a response to ASX Price Query. | 24/02/2023 |
Cogstate will release its half year report for the period ending 31 December 2022 (Appendix 4D) to ASX on 28 February 2023. For context, at 01 July 2022, Cogstate had contracted future revenue of $139.1m, of which it expected $29.7m to be recognized as revenue in FY23. Cogstate now expects approximately $5m of that FY23 contracted revenue to be recognized in FY24 ($3.3m from 1H23 and the remainder expected to impact 2H23). The company also noted more confidence in respect of Clinical Trials sales contracts that were expected to positively impact revenue and profitability in 2H23. Current expectations are that some of the larger value contracts are now expected to execute late in 2H23 and therefore will contribute less revenue and profit in FY23 than previously expected, with a larger revenue contribution in FY24, assuming execution. Cogstate advises it expects to report breakeven profit before tax for 1H23. Cogstate executed $27.9m of Clinical Trials sales contracts during 1H23, consistent with the result for the most recent half year of 2H22, taking contracted future revenue at 31 December 2022 to $146.7m (up from $139m at 30 June 2022). The Company provides the following updated guidance in respect of the full year ended 30 June 2023: 2H23 revenue expected to increase over 1H23, but FY23 revenue expected to be approximately 6-9% below FY22; EBITDA is expected to be in the range of 12-15% of revenue (4/Nov/22 guidance of 27-29%); EBIT is expected to be in the range of 6-8% of revenue (4/Nov/22 guidance of 20-24%); and Cash balance as at 31 December 2022 of $29m; expect positive operating cash flow for 2H23. | 24/02/2023 |
The securities of Cogstate Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of CGS, pending the release of an announcement regarding a response to an ASX Price Query. | 23/02/2023 |
listed entity carried for record purposes only | 01/07/2004 |
The suspension of trading in the securities of Cogstate Ltd will be lifted immediately following the release by CGS of an announcement regarding a response to an ASX Price Query. | 24/02/2023 |
The company issues a response to ASX Price Query. | 24/02/2023 |
Cogstate will release its half year report for the period ending 31 December 2022 (Appendix 4D) to ASX on 28 February 2023. For context, at 01 July 2022, Cogstate had contracted future revenue of $139.1m, of which it expected $29.7m to be recognized as revenue in FY23. Cogstate now expects approximately $5m of that FY23 contracted revenue to be recognized in FY24 ($3.3m from 1H23 and the remainder expected to impact 2H23). The company also noted more confidence in respect of Clinical Trials sales contracts that were expected to positively impact revenue and profitability in 2H23. Current expectations are that some of the larger value contracts are now expected to execute late in 2H23 and therefore will contribute less revenue and profit in FY23 than previously expected, with a larger revenue contribution in FY24, assuming execution. Cogstate advises it expects to report breakeven profit before tax for 1H23. Cogstate executed $27.9m of Clinical Trials sales contracts during 1H23, consistent with the result for the most recent half year of 2H22, taking contracted future revenue at 31 December 2022 to $146.7m (up from $139m at 30 June 2022). The Company provides the following updated guidance in respect of the full year ended 30 June 2023: 2H23 revenue expected to increase over 1H23, but FY23 revenue expected to be approximately 6-9% below FY22; EBITDA is expected to be in the range of 12-15% of revenue (4/Nov/22 guidance of 27-29%); EBIT is expected to be in the range of 6-8% of revenue (4/Nov/22 guidance of 20-24%); and Cash balance as at 31 December 2022 of $29m; expect positive operating cash flow for 2H23. | 24/02/2023 |
The securities of Cogstate Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of CGS, pending the release of an announcement regarding a response to an ASX Price Query. | 23/02/2023 |
listed entity carried for record purposes only | 01/07/2004 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 23/08/2024 | Martyn Myer | 100,000 | $1.081 | $108,051 |
| 16/05/2023 | Richard Mohs | 12,000 | $1.150 | $13,800 |
| 07/03/2023 | Martyn Myer | 50,000 | $1.535 | $76,750 |
| 02/03/2023 | Bradley O'Connor | 65,000 | $1.544 | $100,374 |
| 14/09/2021 | Martyn Myer | -250,000 | $1.771 | $442,733 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Martyn Myer | Chairman | 01/10/1999 |
| Bradley O'Connor | CEO | 12/05/2004 |
| Darren Watson | CFO | 01/02/2021 |
| Ingrid Player | Independent Director | 29/08/2019 |
| Kim Wenn | Independent Director | 30/11/2020 |
| Richard van den Broek | Non Exec Director | 26/08/2010 |
| Richard Mohs | Non Exec Director | 20/01/2017 |
| David Franks | Company Secretary | |
| Kristi Geddes | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| David Dolby | Non Exec Director | 24/11/2013 | 25/01/2023 |
| Claire Newstead-Sinclair | CFO | 26/08/2010 | 01/02/2021 |
| Jane McAloon | Independent Director | 27/01/2017 | 21/10/2019 |
| George Hunnewell | COO | 24/11/2016 | 01/05/2018 |
| David Simpson | Non Exec Director | 24/08/2004 | 25/10/2017 |
| Alan Finkel | Non Exec Director | 12/05/2015 | 31/12/2015 |
| Rudy Chapa | Non Exec Director | 22/08/2011 | 15/09/2014 |
| Michael Wooldridge | Non Exec Director | 12/05/2004 | 02/07/2011 |
| Richard Morgan | Non Exec Director | 17/12/1999 | 02/07/2011 |
| Geoffrey Brooke | Non Exec Director | 17/12/1999 | 27/10/2007 |
| Peter Bick | Director, CEO | 17/12/1999 | 13/11/2005 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
